Dover Advisors LLC Acquires New Stake in Novo Nordisk A/S (NYSE:NVO)

Dover Advisors LLC bought a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 7,154 shares of the company's stock, valued at approximately $505,000.

Other hedge funds also recently made changes to their positions in the company. Center for Financial Planning Inc. lifted its position in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after purchasing an additional 123 shares during the period. Strategic Investment Solutions Inc. IL raised its stake in shares of Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after buying an additional 300 shares in the last quarter. Park Square Financial Group LLC acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $29,000. Transce3nd LLC purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $33,000. Finally, Kelly Lawrence W & Associates Inc. CA purchased a new position in Novo Nordisk A/S in the fourth quarter worth $39,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock traded down $1.15 during trading hours on Friday, hitting $79.90. The stock had a trading volume of 7,465,072 shares, compared to its average volume of 7,025,619. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a market capitalization of $358.57 billion, a price-to-earnings ratio of 24.29, a PEG ratio of 0.90 and a beta of 0.66. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $148.15. The stock's fifty day moving average is $67.30 and its two-hundred day moving average is $79.82.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

NVO has been the subject of several research analyst reports. Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. BNP Paribas initiated coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating for the company. Guggenheim cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Wall Street Zen upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $112.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.